Figure 3:

The proposed mechanism of BsAb armed T cell therapy. In this figure, the BsAb armed T cells are a population of T cells collected by apheresis and expanded ex vivo. Those T cells are then armed with an anti-CD3 BsAb with secondary specificity for a tumor antigen. Upon re-infusion into the body, the BsAb armed T cells preferentially collocate at the site of tumor antigen presence where cancer cells exist in the body. Th1 cytokine release ensues and cooperates in tumor cytolysis. The secondary process of additional tumor antigen release and presentation occurs and results in specific activation of endogenous, non-BsAb-armed CD4 and CD8 T cells and an expansion of tumor specific immune response as shown at the bottom right.